233 Studies Now Enrolling
Menu
Search
Status
Medical Condition
- Show all (1752)
- Addiction (19)
- Allergy, Asthma, & Immunology (13)
- All of Us Research Program - NIH (1)
- Autoimmune Disorders (29)
- Blood Disorders (33)
- Bone & Muscle (10)
- Cancer
(564)
- Bladder Cancer (13)
- Brain Cancer (12)
- Breast Cancer (60)
- Gastrointestinal (10)
- Gynecologic Cancer (30)
- Head and Neck Cancer (4)
- Kidney Cancer (7)
- Leukemia (64)
- Liver Cancer (4)
- Lung Cancer (57)
- Lymphoma (24)
- Multiple Myeloma (24)
- Pancreatic Cancer (6)
- Prostate Cancer (25)
- Sarcoma (23)
- Skin Cancer (26)
- Solid Tumors (36)
- Thyroid Cancer (1)
- (-) Uveal Melanoma (7)
- Child Development (4)
- COVID-19 (Coronavirus) (36)
- Critical Illness (1)
- Diabetes (21)
- Ear, Nose and Throat (12)
- Endocrine & Metabolic Disease (12)
- Eye (7)
- Gastrointestinal and Digestive Diseases (26)
- Hair and Skin Disorders (3)
- Headaches (5)
- Healthy Volunteers (187)
- Heart Disease (130)
- Infectious Disease (49)
- Insomnia (2)
- Kidney Disease (12)
- Liver Disease (53)
- Lung Disease (31)
- Meniere's Disease (1)
- Neurological Disorders (165)
- Nutrition (5)
- Obesity (10)
- Obstetrics & Gynecology (55)
- Pain Management (1)
- Pediatrics (103)
- Psychiatric Disorders (67)
- Rehabilitation (9)
- Stroke (7)
- Surgery (7)
- Transplant (48)
- Urology (4)
- Vascular Conditions (10)
Displaying 1 - 19 of 19
Condition: Cancer / Uveal Melanoma
Investigator: Mariam El-Ashmawy, MD, PhD
Status: Closed
This study will develop a data registry of patients diagnosed with uveal melanoma (UM). This registry will provide data that will be used to support the development of novel therapies for this disease. In this study, we are focused on trying to better understand how uveal melanoma behaves and how it is treated at different medical centers around the country.
Condition: Cancer / Pediatric Solid Tumors
Investigator: Nobuko Hijiya, MD
Status: Closed
We are testing new experimental drugs such as selinexor in the hopes of finding a treatment that may be effective against tumors that have come back or that have not responded to standard therapy. The goals of this study are: To find the highest safe dose of selinexor that can be given without causing severe side effects; To learn what kind of side effects…
Condition: Cancer / Uveal Melanoma
Investigator: Richard Carvajal, MD
Status: Closed
The purpose of this study is evaluate the benefits and safety of using the combination of drugs, AEB071 and BYL719 to treat patients with an advanced form of uveal melanoma. The study will have two parts. The first part twill test different dose levels of each drug.Once the highest safe dose level is found, another group of patients will be treated at that…
Condition: Cancer / Pediatric Solid Tumors
Investigator: Alice Lee, MD
Status: Closed
This study is being carried out by the Childrens Oncology Group (COG) Phase 1 Consortium. COG is an international research group that consists of more than 200 hospitals that treat children with cancer in the United States, Canada, Australia, and Switzerland. The Phase 1 Consortium is the group within COG that consists of 21 hospitals, and participation in…
Evaluating the safety and effectiveness of study drug AMG 228 in patients with Advanced Solid Tumors
Condition: Cancer / Pediatric Solid Tumors
Investigator: Yvonne Saenger, MD
Status: Closed
This study is for patients with the following cancers: advanced non-small cell lung cancer, head and neck cancer, melanoma, colon cancer, or bladder cancer. The purpose of this study is to find out more about the effects of AMG 228 in people and on their cancer. AMG 228 is an experimental drug that is being developed to stimulate the bodys immune system to…
Condition: Cancer / Pediatric Solid Tumors
Investigator: Nobuko Hijiya, MD
Status: Closed
This is a Phase 1 multicenter study of pevonedistat in combination with Temozolomide and Irinotecan in pediatric patients with refractory solid tumors, including CNS tumors and lymphoma. The study treatment is considered experimental because pevonedistat is not approved by the United States (US) Food and Drug Administration (FDA) for treating pediatric…
Condition: Cancer / Pediatric Solid Tumors
Investigator: Julia Glade Bender, MD
Status: Closed
The purpose of this study is to examine the effectiveness and tolerability of a study drug called PF-02341066. Additional goals of this study are to learn how the body handles the study drug as well as determine whether or not PF-02341066 is a beneficial treatment for your tumor This study is for children with a recurrent or progressive tumor or lymphoma…
Condition: Cancer / Uveal Melanoma
Investigator: Richard Carvajal, MD
Status: Closed
You are invited to join voluntarily in a clinical research study to find out if the drug LXS196 alone or in combination with HDM201 is safe and has beneficial effects in people who have metastatic uveal melanoma. The purpose of this study is to determine the highest dose of LXS196 that can be given safely without unacceptable side effects as a single drug…
Condition: Cancer / Pediatric Solid Tumors
Investigator: Julia Glade Bender, MD
Status: Closed
The purpose of this study is to assess the safety and effectiveness of a study drug called axitinib on treating tumors that have returned (recurrent) or have not responded to standard therapy (refractory). Children will take axitinib twice a day for 28 days (1 cycle). Children may take study drug for up to 24 cycles (2 years).
Condition: Cancer / Uveal Melanoma
Investigator: Mariam El-Ashmawy, MD, PhD
Status: Closed
This research study is being done to see if the study drug, IMCgp100, works and is safe as treatment for subjects with uveal melanoma who also test positive for HLA-A*0201. In this study IMCgp100 will be compared to three standard treatments: dacarbazine (a chemotherapy drug), ipilimumab (an immunotherapy drug), or pembrolizumab (an immunotherapy drug).…
Condition: Cancer / Uveal Melanoma
Investigator: Mariam El-Ashmawy, MD, PhD
Status: Closed
The purpose of this study is to find out what effects, good and/or bad, intermittent dosing of the medication Selumetinib will have on you and your uveal melanoma. Selumetinib is a medication that blocks (or turns off) MEK, a protein activated in some uveal melanoma cells. Selumetinib is a MEK inhibitor. Blocking MEK may stop your cancer from growing.
Condition: Cancer / Pediatric Solid Tumors
Investigator: Stergios Zacharoulis, MD
Status: Closed
The purpose of this study is to find out more about how the study drug called entrectinib will be used in children, adolescents and young adults with treatment-resistant solid tumor in brain or body. This is a phase 1/1b study, divided into a dose escalation portion (different dose will be tested) and a dose expansion portion (one dose will be tested) in…
Condition: Cancer / Pediatric Solid Tumors
Investigator: Stergios Zacharoulis, MD
Status: Closed
The purpose of this study is to find out more about how the study drug called talimogene laherparepvec will be used in children/adolescents/young adults with advanced solid tumors not involving the central nervous system that are available for direct injection. This is a phase 1 study, multicenter, open-label study, that means all subject enrolled in the…
Condition: Cancer / Uveal Melanoma
Investigator: Richard Carvajal, MD
Status: Closed
This is a Phase I study of a weekly intra-patient escalation dose regimen with IMCgp100 in patients with metastatic uveal melanoma (mUM). To help decide whether or not patients can take part in a research study looking at a new form of treatment for advanced uveal melanoma, their blood need to first be tested to determine their Human Leukocyte Antigen (HLA…
Condition: Cancer / Pediatric Solid Tumors
Investigator: Alice Lee, MD
Status: Closed
This is a phase 1/2 multicenter study of AZD1775 (MK-1775) that will be given in combination with irinotecan. The study treatment is considered experimental because it is not approved by the United States (US) Food and Drug Administration (FDA) for treating children and young adults with solid tumors which have come back or have not responded to standard…
A study for children with refractory solid tumors, including CNS tumors using study drug ramucirumab
Condition: Cancer / Pediatric Solid Tumors
Investigator: Alice Lee, MD
Status: Closed
The goals of this study are to find the highest safe dose of ramucirumab that can be given without causing severe side effects, to learn what kind of side effects ramucirumab can cause, to learn more about the effects of ramucirumab on cells and proteins in the blood and to determine whether ramucirumab is a beneficial treatment for patients with solid…
Condition: Cancer / Uveal Melanoma
Investigator: Richard Carvajal, MD
Status: Closed
The purpose of the treatment part of the study is to find out what effects drug crizotinib has, good and/or bad on people with "high risk" uveal melanoma after surgery or radiation for the eye. It is thought that giving crizotinib to patients with "high risk" uveal melanoma can lower the chance the cancer will come back. Uveal melanoma…
Condition: Cancer / Pediatric Solid Tumors
Investigator: Alice Lee, MD
Status: Closed
This is a Phase 1 multicenter study of a drug called ABI-009 (nab-Rapamycin) in combination withtemozolomide and irinotecan in children and young adults with solid tumors (including CNS tumors)which have come back or have not responded to standard therapy. The study is considered experimental because ABI-009 (nab-Rapamycin) is not approved by the United…
Condition: Cancer / Pediatric Solid Tumors
Investigator: Luca Szalontay, MD
Status: Closed
The purpose of this study is to learn what kind of side effects nivolumab as a single agent and nivolumab in combination with ipilimumab can cause and if these treatments are beneficial for solid tumors. Nivolumab (Dose Level 1) will be given as an intravenous infusion every 14 days of a 28 day cycle. If Dose Level 1 is not tolerable, then it will be…